Skip to main content
. 2023 Mar 9;11:1143019. doi: 10.3389/fpubh.2023.1143019

Table 1.

Comparison of demographic and clinical characteristics between cognitive impairment and NCI.

Variables Overall (N = 733) NCI (N = 611) Early cognitive impairment (N = 122) P-value
Age, years, mean (SD) 66.37 (10.88) 64.72 (10.74) 74.60 (7.28) <0.001*
Sex (Male), n (%) 359 (48.98) 300 (49.10) 59 (48.36) 0.881
Current smoker, n (%) 225 (30.70) 194 (31.75) 31 (25.41) 0.166
Current drinker, n (%) 189 (25.78) 163 (26.68) 26 (21.31) 0.216
Marital status, n (%)
Married 713 (97.27) 594 (97.22) 119 (97.54) 0.841
Unmarried, divorced or widowed 20 (2.73) 17 (2.78) 3 (2.46)
Educational levels, n (%) <0.001*
Primary school or below 285 (38.88) 200 (32.73) 85 (69.67)
Junior high school or senior high school 402 (54.84) 365 (59.74) 37 (30.33)
University or above 46 (6.28) 46 (7.53) 0 (0.00)
Type of work, n (%) <0.001*
Manual labor 392 (53.48) 297 (48.61) 95 (77.87)
Mental labor 101 (13.78) 98 (16.04) 3 (2.46)
Both manual and brain labor 240 (32.74) 216 (35.35) 24 (19.67)
Estimated duration of hypertension, months, median [IQR] 115 [59.00,160.00] 107 [57.00,156.00] 131 [67.00,196.00] 0.018*
Average salt intake per month, g, median [IQR] 300 [180.00, 600.00] 300 [180.00, 600.00] 300 [240.00, 480.00] 0.152
SBP, mmHg, mean (SD) 142.76 (14.73) 142.24 (14.08) 145.39 (17.49) 0.063
DBP, mmHg, mean (SD) 83.69 (12.94) 83.88 (13.42) 82.77 (10.19) 0.301
Waist circumference, cm, mean (SD) 84.21 (15.32) 83.35 (15.74) 88.51 (12.18) <0.001*
Hip circumference, cm, mean (SD) 97.67 (12.34) 96.78 (12.35) 102.14 (11.35) <0.001*
BMI, kg/m2, mean (SD) 24.99 (3.31) 24.90 (3.32) 25.47 (3.23) 0.082
Sleep parameters
Night sleep initiation time, hour, mean (SD) 21.68 (0.91) 21.75 (0.94) 21.38 (0.73) <0.001*
Night sleep duration, hours, mean (SD) 7.11 (0.89) 7.14 (0.86) 6.98 (1.04) 0.113
Night sleep latency, minutes, median [IQR] 20 [10.00, 30.00] 20 [10.00, 30.00] 30 [20.00, 30.00] <0.001*
PSQI score, points, mean (SD) 6.11 (3.87) 5.79 (3.97) 7.75 (2.83) <0.001*
Physical activity, n (%) <0.001*
Light 143 (19.51) 101 (16.53) 42 (34.43)
Moderate 399 (54.43) 330 (54.01) 69 (56.56)
Vigorous 191 (26.06) 180 (29.46) 11 (9.02)
Laboratory testing parameters
FBG, mmol/L, mean (SD) 6.54 (2.10) 6.50 (2.09) 6.71 (2.16) 0.314
TG, mmol/L, mean (SD) 1.68 (1.28) 1.70 (1.34) 1.54 (0.85) 0.090
TC, mmol/L, mean (SD) 4.64 (1.27) 4.68 (1.28) 4.44 (1.22) 0.057
LDL-C, mmol/L, mean (SD) 2.73 (1.02) 2.76 (1.03) 2.57 (0.95) 0.060
SCr, μmoI/L, median [IQR] 66 [55.00, 78.30] 65 [54.70, 77.00] 71 [60.30, 88.00] <0.001*
Imaging parameters
RAD, mm, mean (SD) 33.13 (5.75) 32.84 (5.57) 34.57 (6.38) 0.006*
LAD, mm, mean (SD) 36.65 (5.92) 36.24 (5.72) 38.73 (6.50) <0.001*
RVD, mm, mean (SD) 21.97 (3.18) 21.85 (3.00) 22.57 (3.91) 0.056
LVD, mm, mean (SD) 47.51 (6.51) 47.15 (6.58) 49.29 (5.85) 0.001*
Family history, n (%)
Family history of hypertension 446 (60.85) 380 (62.19) 66 (54.10) 0.094
Family history of CHD 203 (27.69) 173 (28.31) 30 (24.59) 0.401
Family history of hyperlipemia 169 (23.06) 145 (23.73) 24 (19.67) 0.331
Medication information, n (%)
CCBs use 443 (60.44) 366 (59.90) 77 (63.12) 0.508
ACEI/ARBs use 472 (64.39) 407 (66.61) 65 (53.28) 0.005*
Beta-blockers use 139 (18.96) 124 (20.30) 15 (12.30) 0.040*
Diuretics use 128 (17.46) 106 (17.35) 22 (18.03) 0.856

Data are presented as mean (SD), median [IQR], or n (%).

NCI, no cognitive impairment; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; SCr, serum creatinine; RAD, right atrial diameter; LAD, left atrial diameter; RVD, right ventricular diameter; LVD, left ventricular diameter; CHD, coronary heart disease; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.

*

Statistically significant (P < 0.05).